235 related articles for article (PubMed ID: 7906694)
1. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
[TBL] [Abstract][Full Text] [Related]
2. erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection.
Motojima K; Furui J; Kohara N; Izawa K; Kanematsu T; Shiku H
Surgery; 1994 Mar; 115(3):349-54. PubMed ID: 7907434
[TBL] [Abstract][Full Text] [Related]
3. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of potential oncogene alterations in the ENU1564 rat mammary tumor model.
Hal DG; Stoica G
Anticancer Res; 1994; 14(2A):481-7. PubMed ID: 7912494
[TBL] [Abstract][Full Text] [Related]
5. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.
Slebos RJ; Kibbelaar RE; Dalesio O; Kooistra A; Stam J; Meijer CJ; Wagenaar SS; Vanderschueren RG; van Zandwijk N; Mooi WJ
N Engl J Med; 1990 Aug; 323(9):561-5. PubMed ID: 2199829
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
7. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.
Sugio K; Ishida T; Yokoyama H; Inoue T; Sugimachi K; Sasazuki T
Cancer Res; 1992 May; 52(10):2903-6. PubMed ID: 1581907
[TBL] [Abstract][Full Text] [Related]
8. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas.
Yi ES; Harclerode D; Gondo M; Stephenson M; Brown RW; Younes M; Cagle PT
Mod Pathol; 1997 Feb; 10(2):142-8. PubMed ID: 9127320
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A
Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679
[TBL] [Abstract][Full Text] [Related]
10. Human lung cancers growing on extracellular matrix: expression of oncogenes and growth factors.
Pavelic K; Antonic M; Pavelic L; Pavelic J; Pavelic Z; Spaventi S
Anticancer Res; 1992; 12(6B):2191-6. PubMed ID: 1363516
[TBL] [Abstract][Full Text] [Related]
11. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
[TBL] [Abstract][Full Text] [Related]
12. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
13. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
14. Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras.
Volm M; Mattern J
Anticancer Res; 1993; 13(6A):2021-5. PubMed ID: 8297109
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of specific KRAS mutations in lung adenocarcinomas.
Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768
[TBL] [Abstract][Full Text] [Related]
16. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
[TBL] [Abstract][Full Text] [Related]
17. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
[TBL] [Abstract][Full Text] [Related]
18. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
19. [Detection of K-ras oncogene activation in human lung cancer and its possible clinical application].
Zhang G; Sun Y; Wang M
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct; 18(5):282-4, 317. PubMed ID: 8762479
[TBL] [Abstract][Full Text] [Related]
20. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features.
Yamada T; Nakamori S; Ohzato H; Oshima S; Aoki T; Higaki N; Sugimoto K; Akagi K; Fujiwara Y; Nishisho I; Sakon M; Gotoh M; Monden M
Clin Cancer Res; 1998 Jun; 4(6):1527-32. PubMed ID: 9626473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]